Remdesivir was originally developed for infectious viral diseases and is not yet licensed or approved anywhere to treat Covid-19. Photo: Reuters
Remdesivir was originally developed for infectious viral diseases and is not yet licensed or approved anywhere to treat Covid-19. Photo: Reuters

Antiviral drug remdesivir shows mixed results in treating Covid-19 patients

  • No significant benefits seen in Chinese clinical trial but researchers say sample size was smaller than targeted
  • US government-led study meanwhile finds patients with ‘advanced’ symptoms recovered faster than those given placebo

Topic |   Coronavirus pandemic
Remdesivir was originally developed for infectious viral diseases and is not yet licensed or approved anywhere to treat Covid-19. Photo: Reuters
Remdesivir was originally developed for infectious viral diseases and is not yet licensed or approved anywhere to treat Covid-19. Photo: Reuters
READ FULL ARTICLE